Astramorph Pf

ANDA 71051, held by Fresenius Kabi USA. Morphine Sulfate.

As of Nov 15, 2026, ANDA 71051 (Astramorph Pf), held by Fresenius Kabi USA, was first approved by FDA on Oct 7, 1986, with 9 approved supplements and 0 published complete response letters.

First approved: Oct 7, 1986
Supplements approved: 9
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 10 submissions below

Date	Submission	Status	Documents
Oct 7, 1986	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Astramorph Pf0.5MG/ML · injectable;injection	Morphine Sulfate	Discontinued

All 10 submissions, including labeling and manufacturing supplements


Oct 21, 2005	Supplement 14Labeling	Approved	None posted
Sep 30, 2004	Supplement 13Labeling	Approved	None posted
Oct 2, 2002	Supplement 12Labeling	Approved	None posted
Dec 22, 1997	Supplement 10Manufacturing	Approved	None posted
May 31, 1996	Supplement 9Manufacturing	Approved	None posted
Aug 25, 1995	Supplement 8Manufacturing	Approved	None posted
May 3, 1989	Supplement 7Labeling	Approved	None posted
Apr 19, 1988	Supplement 6Manufacturing	Approved	None posted
Apr 19, 1988	Supplement 5Manufacturing	Approved	None posted
Oct 7, 1986	Original application	Approved	None posted

Identifiers

Application: ANDA 71051
Drugs@FDA: Overview at FDA
Company: Fresenius Kabi USA

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters